MaxCyte just gave investors a sentiment check. The stock slipped about 5% to US$1.32 today even though Q2 revenue of US$7.3 million came in ahead of management’s own expectations and marked a sequential pickup from Q1. The real headline is not the loss per share. It is that MaxCyte is leaning on very high gross margins of 77% and a cash balance of about US$142 million to buy time for its cell engineering bets to pay off.

Is MaxCyte’s premium 4.6x P/S ratio a sign the market expects that 21.1% revenue growth to eventually justify today’s pricing, or is enthusiasm already priced in? Compare the stock’s current multiples with our valuation analysis for MaxCyte.

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs Q2 2025): US$7.27m vs….